Lyrica Cr
NDC Package 0071-1027-01

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Lyrica Cr is a medication used to treat pain caused by nerve damage due to diabetes or shingles (herpes zoster) infection. Marketed by Parke-davis Div Of Pfizer Inc, this product is identified by NDC 0071-1027 and is authorized under FDA application NDA209501.

Identification & Billing

NDC Package Code
0071-1027-01
Package Description
30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE
Product Code
0071-1027
11-Digit Billing Format
00071102701
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
30 EA

Clinical Specifications

Proprietary Name
Lyrica Cr
Dosage Form
-
Usage Information
This medication is used to treat pain caused by nerve damage due to diabetes or shingles (herpes zoster) infection.

Regulatory & Marketing

Labeler Name
Parke-davis Div Of Pfizer Inc
FDA Application #
NDA209501
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
01-01-2018
End Marketing Date
11-30-2025
Listing Expiration
11-30-2025
Exclude Flag
D
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0071-1027-01 identifies a specific commercial package of 30 tablet, film coated, extended release in 1 bottle of Lyrica Cr, labeled by Parke-davis Div Of Pfizer Inc. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Parke-davis Div Of Pfizer Inc on January 01, 2018. The current certification is valid through November 30, 2025.

What are the primary indications for this medication?

This medication is used to treat pain caused by nerve damage due to diabetes or shingles (herpes zoster) infection.

How is this Parke-davis Div Of Pfizer Inc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00071102701. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 30 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0071-1027-01
11-Digit CMS (5-4-2)
00071-1027-01

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.